Patents by Inventor Joseph Harris
Joseph Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050249629Abstract: A solid phos-copper base or silver-phos-copper base brazing alloy component for forming a brazed joint with a raised shoulder, little to no black oxide, and improved corrosion resistance. The brazing alloys of the present invention are visually distinguishable from copper and copper alloy parts. The solid brazing components of the present invention may be used in forming brazed joints at low brazing temperatures and result in a joint that is strong, ductile, smooth and corrosion resistant. The solid brazing components are provided in the form of wire, strip, foil or preform, and thus are advantageously used in a wide variety of brazing applications including copper tubing. The brazing components of the present invention are made of an alloy having a liquidus temperature above 840° F. and consist essentially of about 4-9% phosphorus, about 0.1-10% tin, up to about 4% antimony, about 0.1-15% nickel, up to about 3% silicon, up to about 18% silver, up to about 3% manganese, with the balance being copper.Type: ApplicationFiled: July 28, 2003Publication date: November 10, 2005Applicant: J.W. Harris Co., Inc.Inventor: Joseph Harris
-
Publication number: 20050244542Abstract: In one aspect, the present invention provides methods for producing milk by limited proteolysis that is resistant to acid coagulation without negatively affecting the organoleptic properties of the milk. In another aspect, the invention provides methods for increasing the absorbability of calcium in milk to a desired level. In another aspect, the invention provides methods for increasing the viscosity of milk to a desired level. In a further aspect, the invention provides methods for producing acidified milk without coagulation. The methods of the invention comprise the steps of heating milk to a temperature between about 40° C. and about 90° C. and treating the milk with an effective amount of one or more protease. The invention also provides milk that is resistant to acid coagulation, milk with an increased viscosity, stably acidified milk, and products made with the milks of the invention.Type: ApplicationFiled: May 5, 2003Publication date: November 3, 2005Applicants: Novozymes A/S, Chr. Hansen. A/SInventors: Jorge Florin-Christensen, Joseph Harris
-
Patent number: 6766541Abstract: In a preferred embodiment, a joint for joining a first panel and a second panel of a portable restroom includes a first jaw section, a second jaw section, and an outer bumper section. The first jaw section is adapted to allow insertion and removal of the first panel along a first axis and to provide engagement to the first panel in all directions perpendicular to the first axis. The second jaw section is adapted to allow insertion and removal of the second panel along a second axis and to provide engagement to the second panel in all directions perpendicular to the second axis. The outer bumper section has a first edge connected to the first jaw section and a second edge connected to the second jaw section.Type: GrantFiled: November 20, 2002Date of Patent: July 27, 2004Assignee: Five Peaks TechnologyInventors: Reginald Ellis Adams, Daniel Scott Sommerfeld, David Joseph Harris, William Jay Kelley
-
Patent number: 6754333Abstract: The present invention is directed to a contact center and methodology for servicing non-real-time contacts. The advance time for the non-real-time contacts is determined by subtracting the time of service for an earlier item from the time of service for a later item. Items that are serviced immediately after certain types of predetermined events, e.g., the queue containing the non-real-time contacts has no working agents; the queue is empty; the system clock is changed; and the system is rebooted are ignored in estimating the wait time for enqueued items. Using this methodology, accurate wait-time predictions are provided for more efficient management of the contact center.Type: GrantFiled: August 17, 2000Date of Patent: June 22, 2004Assignee: Avaya Technology Corp.Inventors: Andrew D. Flockhart, Michael Joseph Harris
-
Patent number: 6744773Abstract: A multi-domain telephony application programming interface is disclosed for managing a multimedia call across a plurality of domains. Advanced addressing techniques are utilized to support a media independent call control model across multiple communication domains in a consistent and integrated manner. In an illustrative embodiment, the multi-domain telephony application programming interface is based on the Java Telephony API (JTAPI). The multi-domain telephony application programming interface recognizes a call between two domains as one call on both systems, and presents the calls together as a single transaction to a user application. The multi-domain telephony application programming interface identifies and manages a set of inter-domain addresses that are the egress and access points between two domains, so that calls can traverse between them.Type: GrantFiled: August 13, 1998Date of Patent: June 1, 2004Assignee: Avaya Technology Corp.Inventors: Michael Joseph Harris, William Kovar
-
Publication number: 20040093664Abstract: In a preferred embodiment, a joint for joining a first panel and a second panel of a portable restroom includes a first jaw section, a second jaw section, and an outer bumper section. The first jaw section is adapted to allow insertion and removal of the first panel along a first axis and to provide engagement to the first panel in all directions perpendicular to the first axis. The second jaw section is adapted to allow insertion and removal of the second panel along a second axis and to provide engagement to the second panel in all directions perpendicular to the second axis. The outer bumper section has a first edge connected to the first jaw section and a second edge connected to the second jaw section.Type: ApplicationFiled: November 20, 2002Publication date: May 20, 2004Applicant: Five Peaks TechnologyInventors: Reginald Ellis Adams, Daniel Scott Sommerfeld, David Joseph Harris, William Jay Kelley
-
Patent number: 6481432Abstract: A paintball hopper for connection to a paintball launcher or marker has a counter which includes a flexible potentiometer extending into a transfer conduit that connects to the paintball launcher or marker. The hopper has a reservoir shaped for movement of the paintballs toward the transfer conduit. The hopper has a nose with slanted surfaces that are deflection engineered to enhance the deflectability of paintballs directed at the user. The counter mechanism includes a timer and an LCD display so the user can see how many paintballs have been launched and monitor time. The hopper also includes an agitator to agitate the paintballs in the reservoir.Type: GrantFiled: April 19, 2001Date of Patent: November 19, 2002Assignee: American International Marketing, Inc.Inventors: Ennis Rushton, Douglas M. Odom, Mark Wenzel, Joseph Harris, Gregory Misbach, Gordon B. Langford
-
Patent number: 6348195Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: June 26, 2000Date of Patent: February 19, 2002Assignee: Memorial Sloan Kettering Cancer CenterInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Publication number: 20010039945Abstract: A paintball hopper for connection to a paintball launcher or marker has a counter which includes a flexible potentiometer extending into a transfer conduit that connects to the paintball launcher or marker. The hopper has a reservoir shaped for movement of the paintballs toward the transfer conduit. The hopper has a nose with slanted surfaces that are deflection engineered to enhance the deflectability of paintballs directed at the user. The counter mechanism includes a timer and an LCD display so the user can see how many paintballs have been launched and monitor time. The hopper also includes an agitator to agitate the paintballs in the reservoir.Type: ApplicationFiled: April 19, 2001Publication date: November 15, 2001Inventors: Ennis Rushton, Douglas M. Odom, Mark Wenzel, Joseph Harris, Gregory Misbach, Gordon B. Langford
-
Patent number: 6124106Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: March 10, 1999Date of Patent: September 26, 2000Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5952484Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: December 5, 1996Date of Patent: September 14, 1999Assignee: Sloan-Kettering Cancer CenterInventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: 5646253Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.Type: GrantFiled: March 8, 1994Date of Patent: July 8, 1997Assignees: Memorial Sloan-Kettering Cancer Center, Scotgen Biopharmaceuticals, Inc.Inventors: Thomas Paul Wallace, William Joseph Harris, Francis Joseph Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Patent number: D499175Type: GrantFiled: July 16, 2002Date of Patent: November 30, 2004Assignee: Five Peaks Technology, LLCInventors: William Jay Kelley, Daniel Scott Sommerfeld, David Joseph Harris, Reginald Ellis Adams